Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

December 22, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

July 31, 2027

Conditions
Prostate Cancer
Interventions
DRUG

Lutetium Lu 177 JH020002 Injection

Patients will receive Lutetium Lu 177 JH020002 Injection every 6 weeks for a maximum of 6 doses. Doses range between 1.85 and 8.88 GBq (50-240 mCi)

Trial Locations (13)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

Unknown

RECRUITING

Anhui Provincial Hospital, Hefei

RECRUITING

Peking University First Hospital, Beijing

RECRUITING

The First Affiliated Hospital of Fujian Medical University, Fuzhou

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

RECRUITING

Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital, Wuhan

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

NOT_YET_RECRUITING

Affiliated Hospital of Jiangsu University, Wuxi

RECRUITING

Shandong Cancer Hospital, Jinan

RECRUITING

West China Hospital of Sichuan University, Chengdu

RECRUITING

Tianjin Cancer Hospital Airport Hospital, Tianjin

RECRUITING

Zhejiang Provincial People's Hospital, Hangzhou

Sponsors
All Listed Sponsors
lead

Bivision Pharmaceuticals, Inc.

INDUSTRY